Melinda Mosby, NP
Psychiatric/Mental Health · Jackson, TNNPI 1548445562
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (60.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Teva Pharmaceuticals USA, Inc. accounts for 74.9% of it on its own, with 15 other manufacturers making up the rest. Among psychiatric/mental health clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 239 payments — averaging $53.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$10K
- Neurocrine Biosciences, Inc.$426
- Johnson & Johnson$383
- AbbVie$348
- Lundbeck LLC$341
- Indivior Inc.$332
- plus $1K from 10 others
What the payments were for
- Speaking & faculty fees$7,64360%
- Travel & lodging$8747%
- Food & beverage$4,22933%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 54 | $9,548 |
| Neurocrine Biosciences, Inc. | 38 | $426 |
| Johnson & Johnson | 23 | $383 |
| AbbVie | 24 | $348 |
| Lundbeck LLC | 15 | $341 |
| Indivior Inc. | 19 | $332 |
| Alkermes, Inc. | 12 | $305 |
| E.r. Squibb & Sons, L.L.C. | 19 | $262 |
| Otsuka America Pharmaceutical, Inc. | 8 | $221 |
| Vanda Pharmaceuticals Inc. | 9 | $197 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $169 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $79 |
| Supernus Pharmaceuticals, Inc. | 3 | $68 |
| Sunovion Pharmaceuticals Inc. | 2 | $39 |
| AstraZeneca | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,746 in reported general payments places this provider in the 95th percentile of 1,167 psychiatric/mental health providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 52 | $140,502 |
| IngrezzaValbenazine Tosylate | 13 | $109,743 |
| Abilify MaintenaAripiprazole | 21 | $46,617 |
| FanaptIloperidone | 12 | $41,256 |
| UzedyRisperidone | 11 | $33,087 |
| VraylarCariprazine Hcl | 21 | $30,042 |
| CaplytaLumateperone Tosylate | 12 | $22,912 |
| SaphrisAsenapine Maleate | 12 | $14,978 |
| Paliperidone ErPaliperidone | 27 | $8,099 |
| Oxcarbazepine | 104 | $5,793 |
| Chlorpromazine Hcl | 29 | $3,755 |
| Trazodone Hcl | 272 | $3,596 |
| Hydroxyzine Hcl | 173 | $3,116 |
| Buspirone Hcl | 170 | $2,984 |
| Haloperidol Decanoate | 69 | $2,793 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $383 | $140,50252 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $426 | $109,74313 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $221 | $46,61721 claims |
| AbbVieVraylar, Saphris | $348 | $45,02033 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $197 | $41,25612 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $9,548 | $33,08711 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $169 | $22,91212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,167 psychiatric/mental health providers in Tennessee.
Other psychiatric/mental health in Jackson
- Anna CookJackson$54K
- Inyang MorrisJackson$8K
- Laura MelaroBolivar$682K
- Fay BembryJohnson City$449K
- Kristian DambrinoNashville$449K
- Mary AllenMemphis$422K
- Lauren HansenNashville$263K
- Joshua ThompsonChattanooga$262K
- Kristal HurstBlaine$260K
- Kaitlynn EarlsGreeneville$228K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.